We are pleased to welcome Dr. Steve Yang, who is joining WuXi as Executive Vice President and Chief Operating Officer. Dr. Yang is a pharmaceutical industry leader recognized for building R&D capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai. He and his team transformed the mission of AstraZeneca Innovation Center China; delivered AstraZeneca’s first preclinical drug candidate discovered in China; strengthened translational science capabilities; established research outsourcing strategic partnerships; and facilitated and managed a series of scientific collaborations in China, Russia, Israel, Taiwan, and Korea. Dr. Yang also previously served as Vice President and Head of Asia R&D at Pfizer.
We are very pleased to announce that Edward Hu will assume additional responsibilities as WuXi’s Chief Investment Officer in addition to his current role as Chief Financial Officer. As Chief Investment Officer, Mr. Hu will be responsible for company-wide investments, including strategic investments in new businesses, corporate venture capital investments, mergers and acquisitions, and joint ventures. Mr. Hu spearheaded efforts to build many of WuXi’s new businesses, including biologics, toxicology, genomics, and clinical trial services in China. He led the acquisition and integration of AppTec, Abgent, and MedKey. He also created and has managed our joint ventures with MedImmune to co-develop an innovative biologics product in China, and with PRA to create a clinical CRO in China that meets the highest international standards.
With these new appointments, we look forward to further strengthening our organization as we continue our mission to build the best R&D platform to enable anyone and any company to discover and develop healthcare products to benefit patients.